Improvement in facial erythema within 30 minutes of initial application of brimonidine tartrate in patients with rosacea

Journal of Drugs in Dermatology

Volumn 13, Issue 6, 2014, Pages 699-704

  Jackson, J Mark ^a   Fowler, Joseph ^a   Moore, Angela ^b   Jarratt, Michael ^c   Jones, Terry ^d   Meadows, Kappa ^e   Steinhoff, Martin ^f   Rudisill, Diane ^g   Leoni, Matthew ^g  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b Arlington Center for Dermatology   (United States)

^c DermResearch Inc   (United States)

^d J and S Studies Inc   (United States)

^e The Education and Research Foundation Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Galderma RandD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DERMATOLOGICAL AGENT; GEL; QUINOXALINE DERIVATIVE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FACE ERYTHEMA; FEMALE; GEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEA; TREATMENT RESPONSE; ADOLESCENT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ERYTHEMA; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; DOUBLE-BLIND METHOD; ERYTHEMA; FEMALE; GELS; HUMANS; MALE; MIDDLE AGED; QUINOXALINES; ROSACEA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903398026     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51:327-41. (Pubitemid 39178655)
2. Wilkin J, Dahl M, Detmar M et al. Standard classification of rosacea: report of the National Rosacea Society expert committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46:584-7.
3. Odom R, Dahl M, Dover J et al. Standard management options for rosacea, Part I: overview and broad spectrum of care. Cutis. 2009;84:43-7.
4. Del Rosso JQ. Advances in understanding and managing rosacea: part 1. Connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol. 2012;5(3):16-25.
5. Steinhoff M, Buddenkotte J, Aubert J et al. Clinical, cellular and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15:2-11.
6. Del Rosso JQ. Advances in understanding and managing rosacea: part 2. The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5(3):26-36.
7. Fowler J, Jarratt M, Moore A et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166:633-41.
8. Wolf JE Jr, Del Rosso JQ. The CLEAR trial: results of a large community-based study of metronidazole gel in rosacea. Cutis. 2007;79:73-80.
9. Gupta AK, Chaudhry MM. Rosacea and its management: an overview. J Eur Acad Dermatol Venereol. 2005;19:273-85. (Pubitemid 40691703)
10. Sneddon IB. A clinical trial of tetracycline in rosacea. Br J Dermatol. 1966;78:649-52.
11. Sauder DN, Miller R, Gratton D et al. The treatment of rosacea: the safety and efficacy of sodium sulfacetamide 10% and sulfur 5% lotion (Novacet) is demonstrated in a double-blind study. J Dermatol Treat. 1997;8:79-85. (Pubitemid 27338511)
12. Carmichael AJ, Marks R, Graupe KA et al. Topical azelaic acid in the treatment of rosacea. J Dermatol Treat. 1993;4 Suppl I:S19-22. (Pubitemid 23216497)
13. Serle JB. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv Ophthalmol. 1996;41 Suppl 1:S39-47. (Pubitemid 26422592)
14. Piwnica D, Rosignoli C, Cazereth S et al. Vasoconstriction and anti-inflammatory properties of the alpha adrenergic receptor agonist brimonidine. Poster presented at International Investigative Dermatology 2013 Abstract 0138.
15. Katz LJ on behalf of the Brimonidine study group. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Am J Ophthalmol. 1999;127:20-6.
16. Fowler J, Jackson JM, Moore A et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650-6. Do Not Penalties
17. th March 2014.